Single-Cell Omics Technologies Reveal the Molecular Mechanism by Which Ebselen Inhibits SQSTM1-Mediated Ubiquitination to Reverse Colorectal Cancer Resistance to Cisplatin

Colorectal cancer is one of the most common cancers worldwide, and its resistance to the chemotherapeutic drug cisplatin complicates treatment. Ebselen, a promising antioxidant, has demonstrated inhibitory effects on various cancer cell lines. This study aims to explore the molecular mechanisms by which Ebselen modulates ubiquitination modifications to improve cisplatin resistance using single-cell omics technology